Source comparison
BPC-157 KPV for Leaky Gut Research: Peptide Comparison
Mechanism FAK-paxillin pathway activation, VEGF receptor 2 binding, tight junction protein upregulation NF-κB nuclear translocation inhibition via importin complex binding BPC-157 for structural barrier repair; KPV for inflammation-driven permeability Lyophili
This comparison does not assign a generated winner or score.
- Mechanism
- FAK-paxillin pathway activation, VEGF receptor 2 binding, tight junction protein upregulation
- NF-κB nuclear translocation inhibition via importin complex binding
- BPC-157 for structural barrier repair; KPV for inflammation-driven permeability
- Lyophilized: -20°C; Reconstituted: 4°C, use within 14 days
- Complementary mechanisms justify combined protocols in multi-phase injury models
- Effective Dose (in vitro)
- 1–10 μg/mL in culture media
- 10–100 μM in culture media
- Caco-2 monolayers, HT-29 barrier assays
- .
- KPV requires 10× higher molar concentration for equivalent barrier protection
- Effective Dose (in vivo)
- 10 μg/kg IP once daily
- 5 mg/kg IP twice daily
- DSS colitis, TNBS colitis, I/R injury
- BPC-157's longer half-life permits once-daily dosing; KPV needs BID administration
- Peak Effect Timing
- 24–48 hours post-treatment
- 2–12 hours post-treatment
- Time-course studies, acute vs chronic models
- Stagger dosing: KPV at injury induction, BPC-157 at 6h post-injury for temporal coverage
- Primary Outcome Measures
- TEER, claudin-1/occludin expression, VEGF levels, crypt depth
- TNF-alpha, IL-6, histological inflammation scores, myeloperoxidase activity
- Match peptide to primary endpoint
- Use BPC-157 when barrier structure is the endpoint; KPV when inflammation is the readout
- Stability (Reconstituted)
- 8–12% monthly degradation at 4°C
- 15–20% monthly degradation at 4°C
- Aliquot and freeze single-use doses to avoid degradation
- Avoid freeze-thaw cycles
- KPV's tripeptide structure makes it more labile. Prepare fresh working solutions weekly